Because PD-L1 is upregulated on tumor cells following BRAF inhibition, and anti-PD-1 therapy is less toxic compared to anti-CTLA-4, combining BRAFV600E inhibitors with anti-PD-1 therapy seems promising. This evidence concerns the gene CD274 and neoplasm.